{"id":56373,"date":"2023-05-01T13:05:37","date_gmt":"2023-05-01T11:05:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/verastem-oncology-to-participate-in-upcoming-investor-conferences\/"},"modified":"2023-05-01T13:05:37","modified_gmt":"2023-05-01T11:05:37","slug":"verastem-oncology-to-participate-in-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/verastem-oncology-to-participate-in-upcoming-investor-conferences\/","title":{"rendered":"Verastem Oncology to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div>\n<p>BOSTON&#8211;(BUSINESS WIRE)&#8211;Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230501005068\/en\/1777984\/5\/VSTM.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230501005068\/en\/1777984\/21\/VSTM.jpg\"><\/a><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nJMP Securities Life Sciences Conference; podium presentation on Tuesday, May 16, 2023 at 1:00 p.m. ET<\/li>\n<li>\nRBC Capital Markets Global Healthcare Conference; fireside chat on Wednesday, May 17, 2023 at 2:05 p.m. ET<\/li>\n<\/ul>\n<p>\nA live webcast of the presentation and fireside chat will be available on the investors section of the Company\u2019s website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.verastem.com&amp;esheet=53389615&amp;newsitemid=20230501005068&amp;lan=en-US&amp;anchor=www.verastem.com&amp;index=1&amp;md5=5ebd89ad9ebadbdc13b83bae3a9eca22\" rel=\"nofollow noopener\" shape=\"rect\">www.verastem.com<\/a>. An archived replay of the presentation and fireside chat will be made available on the same website for approximately 90 days following each event.<\/p>\n<p>\n<strong>About Verastem Oncology<\/strong><\/p>\n<p>\nVerastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF\/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.verastem.com&amp;esheet=53389615&amp;newsitemid=20230501005068&amp;lan=en-US&amp;anchor=www.verastem.com&amp;index=2&amp;md5=5dd3c0702017d8d31b564ab0904d16b9\" rel=\"nofollow noopener\" shape=\"rect\">www.verastem.com<\/a>.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b><i>Investors:<\/i><\/b><br \/>Dan Calkins<br \/>\n<br \/>+1 781-469-1694<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;&#58;&#x64;&#99;&#x61;&#108;&#x6b;i&#x6e;s&#x40;v&#x65;r&#x61;s&#x74;e&#109;&#x2e;&#99;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">d&#99;&#97;&#x6c;&#x6b;i&#110;&#115;&#x40;&#x76;&#x65;r&#97;&#115;&#x74;&#x65;m&#46;&#99;&#x6f;&#x6d;<\/a><\/p>\n<p>\nNate LiaBraaten<br \/>\n<br \/>+1 212-600-1902<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#x6c;&#x74;&#111;&#x3a;n&#x61;&#x74;&#101;&#x40;a&#x72;&#x67;&#111;&#x74;p&#x61;&#x72;&#116;&#x6e;e&#x72;&#x73;&#46;&#x63;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#110;&#x61;&#116;&#x65;&#64;&#97;&#x72;&#103;&#x6f;t&#x70;a&#114;&#x74;&#110;&#x65;r&#x73;&#x2e;&#99;&#x6f;m<\/a><\/p>\n<p>\n<b><i>Media:<\/i><\/b><br \/>Lisa Buffington<br \/>\n<br \/>+1 (781) 292-4205<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;i&#108;&#x74;o&#58;&#x6c;b&#117;&#x66;f&#105;&#x6e;&#103;&#x74;&#x6f;&#110;&#x40;&#x76;&#101;&#x72;a&#115;&#x74;e&#109;&#x2e;c&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#108;&#x62;&#117;&#x66;&#102;&#x69;n&#x67;t&#x6f;n&#64;&#x76;&#101;&#x72;&#97;&#x73;&#116;&#x65;m&#x2e;c&#x6f;m<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON&#8211;(BUSINESS WIRE)&#8211;Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: JMP Securities Life Sciences Conference; podium presentation on Tuesday, May 16, 2023 at 1:00 p.m. ET RBC Capital Markets Global Healthcare Conference; fireside chat on &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/verastem-oncology-to-participate-in-upcoming-investor-conferences\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-56373","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Verastem Oncology to Participate in Upcoming Investor Conferences - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/verastem-oncology-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Verastem Oncology to Participate in Upcoming Investor Conferences - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOSTON&#8211;(BUSINESS WIRE)&#8211;Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: JMP Securities Life Sciences Conference; podium presentation on Tuesday, May 16, 2023 at 1:00 p.m. ET RBC Capital Markets Global Healthcare Conference; fireside chat on ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/verastem-oncology-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-01T11:05:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230501005068\/en\/1777984\/21\/VSTM.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verastem-oncology-to-participate-in-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verastem-oncology-to-participate-in-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Verastem Oncology to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2023-05-01T11:05:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verastem-oncology-to-participate-in-upcoming-investor-conferences\\\/\"},\"wordCount\":212,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verastem-oncology-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230501005068\\\/en\\\/1777984\\\/21\\\/VSTM.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verastem-oncology-to-participate-in-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verastem-oncology-to-participate-in-upcoming-investor-conferences\\\/\",\"name\":\"Verastem Oncology to Participate in Upcoming Investor Conferences - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verastem-oncology-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verastem-oncology-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230501005068\\\/en\\\/1777984\\\/21\\\/VSTM.jpg\",\"datePublished\":\"2023-05-01T11:05:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verastem-oncology-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verastem-oncology-to-participate-in-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verastem-oncology-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230501005068\\\/en\\\/1777984\\\/21\\\/VSTM.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230501005068\\\/en\\\/1777984\\\/21\\\/VSTM.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/verastem-oncology-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Verastem Oncology to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Verastem Oncology to Participate in Upcoming Investor Conferences - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/verastem-oncology-to-participate-in-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Verastem Oncology to Participate in Upcoming Investor Conferences - Pharma Trend","og_description":"BOSTON&#8211;(BUSINESS WIRE)&#8211;Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in the following upcoming investor conferences: JMP Securities Life Sciences Conference; podium presentation on Tuesday, May 16, 2023 at 1:00 p.m. ET RBC Capital Markets Global Healthcare Conference; fireside chat on ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/verastem-oncology-to-participate-in-upcoming-investor-conferences\/","og_site_name":"Pharma Trend","article_published_time":"2023-05-01T11:05:37+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230501005068\/en\/1777984\/21\/VSTM.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/verastem-oncology-to-participate-in-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/verastem-oncology-to-participate-in-upcoming-investor-conferences\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Verastem Oncology to Participate in Upcoming Investor Conferences","datePublished":"2023-05-01T11:05:37+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/verastem-oncology-to-participate-in-upcoming-investor-conferences\/"},"wordCount":212,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/verastem-oncology-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230501005068\/en\/1777984\/21\/VSTM.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/verastem-oncology-to-participate-in-upcoming-investor-conferences\/","url":"https:\/\/pharma-trend.com\/en\/verastem-oncology-to-participate-in-upcoming-investor-conferences\/","name":"Verastem Oncology to Participate in Upcoming Investor Conferences - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/verastem-oncology-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/verastem-oncology-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230501005068\/en\/1777984\/21\/VSTM.jpg","datePublished":"2023-05-01T11:05:37+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/verastem-oncology-to-participate-in-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/verastem-oncology-to-participate-in-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/verastem-oncology-to-participate-in-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230501005068\/en\/1777984\/21\/VSTM.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230501005068\/en\/1777984\/21\/VSTM.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/verastem-oncology-to-participate-in-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Verastem Oncology to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56373","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=56373"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/56373\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=56373"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=56373"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=56373"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}